Correlative Analysis of Genetic Alterations and Everolimus Benefit in Hormone Receptor Positive, Human Epidermal Growth Factor Receptor 2 Negative Advanced Breast Cancer: Results From BOLERO-2 (vol 34, pg 419, 2016)

被引：1
|
作者：
Hortobagyi, Gabriel N.
Chen, David
Piccart, Martine
Rugo, Hope S.
Burris, Howard A.
Pritchard, Kathleen I.
Campone, Mario
Noguchi, Shinzaburo
Perez, Alejandra T.
Deleu, Ines
Shtivelband, Mikhail
Masuda, Norikazu
Dakhil, Shaker
Anderson, Ian
Robinson, Douglas M.
He, Wei
Garg, Abhishek
McDonald, E. Robert, III
Bitter, Hans
Huang, Alan
Taran, Tetiana
Bachelot, Thomas
Lebrun, Fabienne
Lebwohl, David
Jose, Baselga
机构：
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2019年 / 37卷 / 04期
关键词：
D O I：
10.1200/JCO.18.02265
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：355 / 355
页数：1
相关论文
共 50 条
  • [1] Correlative Analysis of Genetic Alterations and Everolimus Benefit in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Results From BOLERO-2
    Hortobagyi, Gabriel N.
    Chen, David
    Piccart, Martine
    Rugo, Hope S.
    Burris, Howard A., III
    Pritchard, Kathleen I.
    Campone, Mario
    Noguchi, Shinzaburo
    Perez, Alejandra T.
    Deleu, Ines
    Shtivelband, Mikhail
    Masuda, Norikazu
    Dakhil, Shaker
    Anderson, Ian
    Robinson, Douglas M.
    He, Wei
    Garg, Abhishek
    McDonald, E. Robert, III
    Bitter, Hans
    Huang, Alan
    Taran, Tetiana
    Bachelot, Thomas
    Lebrun, Fabienne
    Lebwohl, David
    Baselga, Jose
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (05) : 419 - U79
  • [2] Everolimus plus exemestane for hormone-receptor-positive, human epidermal growth factor receptor-2-negative advanced breast cancer: overall survival results from BOLERO-2
    Piccart, M.
    Hortobagyi, G. N.
    Campone, M.
    Pritchard, K. I.
    Lebrun, F.
    Ito, Y.
    Noguchi, S.
    Perez, A.
    Rugo, H. S.
    Deleu, I.
    Burris, H. A., III
    Provencher, L.
    Neven, P.
    Gnant, M.
    Shtivelband, M.
    Wu, C.
    Fan, J.
    Feng, W.
    Taran, T.
    Baselga, J.
    ANNALS OF ONCOLOGY, 2014, 25 (12) : 2357 - 2362
  • [3] Everolimus plus exemestane for hormone receptor-positive (HR plus ), human epidermal growth factor receptor-2-negative (HER2-) advanced breast cancer (BC): overall survival results from BOLERO-2
    Piccart, M.
    Hortobagyi, G. N.
    Campone, M.
    Pritchard, K. I.
    Noguchi, S.
    Rugo, H.
    Gnant, M.
    Feng, W.
    Taran, T.
    Baselga, J.
    EUROPEAN JOURNAL OF CANCER, 2014, 50 : S1 - S1
  • [4] Everolimus in postmenopausal hormone-receptor-positive Advanced Breast Cancer The Breast Cancer Trials of Oral Everolimus-2 (BOLERO-2)
    Hadoux, J.
    Delaloge, S.
    ONCOLOGIE, 2012, 14 (05) : 349 - 350
  • [5] EVEROLIMUS-ASSOCIATED ADVERSE EVENTS IN POSTMENOPAUSAL WOMEN WITH HORMONE RECEPTOR POSITIVE ADVANCED BREAST CANCER UPDATED RESULTS FROM BOLERO-2
    Campbell-Baird, Cynthia
    ONCOLOGY NURSING FORUM, 2013, 40 (06) : E428 - E428
  • [6] The BOLERO-2 trial: the addition of everolimus to exemestane in the treatment of postmenopausal hormone receptor-positive advanced breast cancer
    Beaver, Julia A.
    Park, Ben H.
    FUTURE ONCOLOGY, 2012, 8 (06) : 651 - 657
  • [7] Correlation of molecular alterations with efficacy of everolimus in hormone-receptor-positive, HER2-negative advanced breast cancer: Results from BOLERO-2.
    Rugo, Hope S.
    Hortobagyi, Gabriel N.
    Piccart-Gebhart, Martine J.
    Burris, Howard A.
    Campone, Mario
    Noguchi, Shinzaburo
    Perez, Alejandra T.
    Deleu, Ines
    Shtivelband, Mikhail
    Provencher, Louise
    Masuda, Norikazu
    Dakhil, Shaker R.
    Anderson, Ian
    Chen, David
    Damask, Amy
    Huang, Alan
    McDonald, Robert
    Taran, Tanya
    Sahmoud, Tarek
    Baselga, Jose
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (26)
  • [8] Correlation of molecular alterations with efficacy of everolimus in hormone receptor-positive, HER2-negative advanced breast cancer: Results from BOLERO-2.
    Hortobagyi, Gabriel N.
    Piccart-Gebhart, Martine J.
    Rugo, Hope S.
    Burris, Howard A.
    Campone, Mario
    Noguchi, Shinzaburo
    Perez, Alejandra T.
    Deleu, Ines
    Shtivelband, Mikhail
    Provencher, Louise
    Masuda, Norikazu
    Dakhil, Shaker R.
    Anderson, Ian
    Chen, David
    Damask, Amy
    Huang, Alan
    McDonald, Robert
    Taran, Tanya
    Sahmoud, Tarek
    Baselga, Jose
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (18)
  • [9] Molecular Alterations and Everolimus Efficacy in Human Epidermal Growth Factor Receptor 2 Overexpressing Metastatic Breast Cancers: Combined Exploratory Biomarker Analysis From BOLERO-1 and BOLERO-3 (vol 34, pg 2115, 2016)
    Burris, Howard A.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (04) : 357 - 357
  • [10] Capivasertib in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative advanced breast cancer
    Qureshi, Zaheer
    Altaf, Faryal
    Khanzada, Mikail
    Zaheer, Zaofashan
    Fatima, Eeshal
    Bakhtiar, Muhammad
    CURRENT PROBLEMS IN CANCER, 2024, 51
12345